Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556075 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis
A Phase 2 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00556075 is a Phase 2 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 67 participants.
The verdict
NCT00556075, a Phase 2 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Proellex is safe and effective for the treatment of symptomatic endometriosis.
Interventions
- DRUG Placebo
- DRUG Proellex 25 mg
- DRUG Proellex 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556075
The ClinicalTrials.gov registry entry for NCT00556075 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00556075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00556075 about?
NCT00556075 is a clinical study titled "Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis". The purpose of this study is to determine whether Proellex is safe and effective for the treatment of symptomatic endometriosis.
What is the current status of trial NCT00556075?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2007-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00556075?
The interventions under investigation include: Placebo (DRUG), Proellex 25 mg (DRUG), Proellex 50 mg (DRUG).
Who is sponsoring clinical trial NCT00556075?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.